Q: I wish I could go to a doctor who could outline a personalized plan for improving and protecting my health, but that’s ...

People taking GLP-1 agonists for diabetes have a significantly lower risk of developing dementia compared to those using ...

For individuals with type 2 diabetes (T2D) and moderate cardiovascular risk treated with metformin, the risk for major ...

The diabetes drug glipizide was linked to a higher risk of serious heart problems compared to dipeptidyl peptidase-4, or DPP4, inhibitors in patients with Type 2 diabetes, according to a study ...

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with reduced type 2 diabetes mellitus (T2DM)-related dementia risk compared with metformin.

A recent trial reveals metformin does not enhance survival in metastatic prostate cancer but offers significant metabolic ...

Background: Subclinical hypothyroidism has been linked to adverse renal outcomes, but it is unknown whether treatment of subclinical hypothyroidism reduces the risk of these adverse outcomes. We ...

Based on microneedles, the system continuously monitors – via the interstitial fluid in the skin – glucose levels and the ...

The researchers studied the five-year risk of major adverse cardiovascular events in patients treated with different sulfonylureas (glimepiride, glipizide, or glyburide) or DPP4i in addition to ...